191 related articles for article (PubMed ID: 12493542)
41. Technetium-99m MAG3, a comparison with iodine-123 and iodine-131 orthoiodohippurate, in patients with renal disorders.
Jafri RA; Britton KE; Nimmon CC; Solanki K; Al-Nahhas A; Bomanji J; Fettich J; Hawkins LA
J Nucl Med; 1988 Feb; 29(2):147-58. PubMed ID: 2964516
[TBL] [Abstract][Full Text] [Related]
42. [A comparison of different methods of calculating clearances using 99mTc-mercaptoacetyltriglycine and 123I- or 131I-ortho-iodohippuric acid].
Keske U; Cordes M; Hosten N; Roll D; Hunger J; Felix R
Nuklearmedizin; 1990 Jun; 29(3):93-100. PubMed ID: 2144045
[TBL] [Abstract][Full Text] [Related]
43. [Parametric representation of kidney function using 99mTc-mercaptoacetyltriglycine (MAG3)].
Szabó Z; Kutkuhn B; Georgescu G; Mecklenbeck W; Suatmadji A; Vosberg H
Nuklearmedizin; 1989 Jun; 28(3):73-83. PubMed ID: 2525703
[TBL] [Abstract][Full Text] [Related]
44. [Simultaneous measumrement of the renal excretion of 131I-hippuran and 99mTc-MAG3].
Schroth HJ; Bialy J; Bühler M; Peters JW; Rink T; Schmidt M; Garth H
Nuklearmedizin; 1994 Jun; 33(3):113-8. PubMed ID: 8090625
[TBL] [Abstract][Full Text] [Related]
45. Study on 99mTc-MAG3 and 99mTc-DMSA renal accumulation using in vitro cellular model.
Nový Z; Mandíková J; Trejtnar F
Ceska Slov Farm; 2011 Feb; 60(1):7-10. PubMed ID: 21648170
[TBL] [Abstract][Full Text] [Related]
46. [Clinical evaluation of 99mTc-MAG3 as a radiotracer to assess the function of transplanted kidney: comparison with 123I-OIH].
Yamamoto K; Takahashi N; Sugimoto K; Yoshida M; Hayashi N; Ishii Y; Nishibuchi S; Muranaka K; Okada K; Miyazaki M
Nihon Igaku Hoshasen Gakkai Zasshi; 1995 May; 55(6):409-13. PubMed ID: 7617467
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of technetium-99m-L,L-EC in renal transplant recipients: a comparative study with technetium-99m-MAG3 and iodine-125-OIH.
Stoffel M; Jamar F; Van Nerom C; Verbruggen A; Mourad M; Leners N; Squifflet JP; Beckers C
J Nucl Med; 1994 Dec; 35(12):1951-8. PubMed ID: 7989976
[TBL] [Abstract][Full Text] [Related]
48. A comparative study of renal scintigraphy and clearance with technetium-99m-MAG3 and iodine-123-hippurate in patients with renal disorders.
Müller-Suur R; Bois-Svensson I; Mesko L
J Nucl Med; 1990 Nov; 31(11):1811-7. PubMed ID: 2146371
[TBL] [Abstract][Full Text] [Related]
49. Technetium-99m-N,N-ethylenedicysteine--a comparative study of renal scintigraphy with technetium-99m-MAG3 and iodine-131-OIH in patients with obstructive renal disease.
Ozker K; Onsel C; Kabasakal L; Sayman HB; Uslu I; Bozluolçay S; Cansiz T; Kapicioğlu T; Urgancioğlu I
J Nucl Med; 1994 May; 35(5):840-5. PubMed ID: 8176468
[TBL] [Abstract][Full Text] [Related]
50. Transport of 99mTc-MAG3 via rat renal organic anion transporter 1.
Shikano N; Kanai Y; Kawai K; Ishikawa N; Endou H
J Nucl Med; 2004 Jan; 45(1):80-5. PubMed ID: 14734677
[TBL] [Abstract][Full Text] [Related]
51. [Phase 3 clinical study of 99mTc-MAG3 injectable, a dynamic renal imaging agent--comparison with 123I-OIH and 99mTc-DTPA].
Torizuka K; Ishibashi A; Ikekubo K; Yamamoto K; Nishibuchi S
Kaku Igaku; 1994 Feb; 31(2):183-98. PubMed ID: 8121074
[TBL] [Abstract][Full Text] [Related]
52. Estimate of relative function and transit time in renographic studies.
González A; Ros D; Pavia J
J Nucl Biol Med (1991); 1994 Sep; 38(3):502-7. PubMed ID: 7865547
[TBL] [Abstract][Full Text] [Related]
53. Radiation dosimetry for technetium-99m-MAG3, technetium-99m-DTPA, and iodine-131-OIH based on human biodistribution studies.
Stabin M; Taylor A; Eshima D; Wooter W
J Nucl Med; 1992 Jan; 33(1):33-40. PubMed ID: 1530968
[TBL] [Abstract][Full Text] [Related]
54. [Evaluation of renal function using 99mTc-MAG3: comparison with 123I-OIH and 99mTc-DTPA].
Takayama T; Aburano T; Shuke N; Yokoyama K; Michigishi T; Sun BF; Tonami N; Hisada K; Takabatake T; Ohta H
Kaku Igaku; 1993 Jul; 30(7):753-60. PubMed ID: 8377298
[TBL] [Abstract][Full Text] [Related]
55. Reproducibility of technetium-99m mercaptoacetyltriglycine clearance in patients with impaired renal function.
Erdil TY; Dede F; Tuglular S; Sen F; Ones T; Farsakoglu Z; Inanir S; Ozener C; Akoglu E; Turoglu T
Nucl Med Commun; 2006 Feb; 27(2):191-6. PubMed ID: 16404234
[TBL] [Abstract][Full Text] [Related]
56. Prediction of renal transplant survival from early postoperative radioisotope studies.
Russell CD; Yang H; Gaston RS; Hudson SL; Diethelm AG; Dubovsky EV
J Nucl Med; 2000 Aug; 41(8):1332-6. PubMed ID: 10945523
[TBL] [Abstract][Full Text] [Related]
57. Administered activity optimization in 99mTc-MAG3 renography for adults.
Díaz MP; Aparicio EE; Rizo OD; Díaz RR; Rodríguez CH
J Nucl Med Technol; 2003 Dec; 31(4):216-21. PubMed ID: 14657288
[TBL] [Abstract][Full Text] [Related]
58. Predictors of Renal Functional Improvement After Pyeloplasty in Ureteropelvic Junction Obstruction: Clinical Value of Visually Assessed Renal Tissue Tracer Transit in
Song SH; Park S; Chae SY; Moon DH; Park S; Kim KS
Urology; 2017 Oct; 108():149-154. PubMed ID: 28595935
[TBL] [Abstract][Full Text] [Related]
59. Optimum sample times for single-injection, multisample renal clearance methods.
Russell CD
J Nucl Med; 1993 Oct; 34(10):1761-5. PubMed ID: 8410295
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetics of (99m)Tc-MAG3.
Vivier PH; Dacher JN
AJR Am J Roentgenol; 2009 Oct; 193(4):W361; author reply W362. PubMed ID: 19770310
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
